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Overview
Taxanes, such as paclitaxel and docetaxel, are widely prescribed chemotherapeutic drugs
[1-3]. They have been used to treat many forms of cancer including breast, ovarian and lung
cancers [1]. Paclitaxel was isolated from the Pacific yew in 1971 and docetaxel, a second
generation taxane, is a semi-synthetic taxane analogue from the European yew identified
approximately 20 years later [2]. The pathway above depicts the known candidate
pharmacogenes involved in the pharmacokinetics and pharmacodynamics of taxanes.
Microtubules display a form of non-equilibrium dynamics referred to as dynamic instability
that is essential to cell division [3]. Dynamic instability is regulated by microtubule-
associated proteins (MAPs) including MAPT, MAP2 and MAP4 [3]. In an un-phosphorylated
state, the MAP proteins bind and stabilize microtubules, leading to cell death [3].
Microtubules are composed of α–tubulin and β–tubulin heterodimers [1]. Taxanes block cell
division by binding to β–tubulin, stabilizing the microtubules, leading to cell death [1,4]. A
3.5A structure of bovine β–tubulin, with bound paclitaxel, can be found in the Protein Data
Bank [5], entry 1JFF [6]. In addition, in vitro studies have shown taxanes to induce BCL2
phosphorylation and apoptosis, with docetaxel doing so at much lower concentrations than
paclitaxel [7,8].
While paclitaxel and docetaxel share many common structural features, their pharmacology
and pharmacokinetics differ somewhat. Consequently, in some patients, solid tumors with
resistance to paclitaxel have been shown to be sensitive to docetaxel [9,10].
The pharmacokinetics of taxanes are complex and are complicated by their different
formulations [11]. Both taxanes are primarily metabolized in the liver and their primary
route of elimination of the parent drug and hydroxylated metabolite is through biliary
excretion via feces [2]. Early work found that docetaxel had linear pharmacokinetics but
paclitaxel did not [2,12]. However, the two taxanes have different formulations: paclitaxel is
dissolved in Cremaphor EL (CrEL, poly-oxyethyleneglycol triricinoleate 35)/ethanol (1:1)
Correspondence to Dr Teri E. Klein, PhD, Department of Genetics, Stanford University Medical Center, 300 Pasteur D. Lane L301,
Mail Code 5120, Stanford, CA 94305-5120, USA, Tel: +1 650 725 0659; fax: +1 650 725 3863; feedback@pharmgkb.org.
NIH Public Access
Author Manuscript
Pharmacogenet Genomics. Author manuscript; available in PMC 2010 December 8.
Published in final edited form as:













where as docetaxel is dissolved in polysorbate 80 (Tween 80) [13]. Tween 80 was found to
alter the fraction of unbound docetaxel in patients [13] and another study found that in the
absence of CrEL, the bioavailability of intraperitoneal paclitaxel was significantly increased
[14]. Various other studies have shown that CrEL alters the pharmacokinetic behavior of
many drugs, including paclitaxel [13,15]. Finally, a small study of the recently available,
130-nm albumin-bound (nab) particle formulation of paclitaxel, devoid of solvents, found
that the disposition of paclitaxel is subject to considerable variability, depending upon the
formulation used [16].
Both paclitaxel [17,18] and docetaxel [17,19-21] are metabolized by CYP3A4. Paclitaxel is
also metabolized by CYP2C8 [22,23], while docetaxel is also metabolized by CYP3A5 [21].
In an in vitro study, a highly significant induction level of PXR (gene NR1I2) -mediated
CYP3A4 expression was observed for paclitaxel, whereas docetaxel only moderately
increased CYP3A4 expression [24]. In another study, paclitaxel activated PXR, but
docetaxel did not [25]. Paclitaxel was also found to activate PXR and enhances P-
glycoprotein (ABCB1) mediated drug clearance [25] and ABCB1 expression [26] as well as
CYP2C8 expression [27].
Both paclitaxel and docetaxel are substrates for the ATP binding cassette multidrug
transporters ABCB1, ABCG2, ABCC1 and ABCC2 [28-34]. OATP1B3 (SLCO1B3) was
identified as the most efficient influx transporter for docetaxel [35] and identified as a key
regulator of paclitaxel hepatic uptake [36,37]. OAT2 (SLC22A7) was found to transport
paclitaxel in in vitro experiments [38].
Taxane resistance is frequent [3,39,40]. Possible mechanisms for such resistance are many,
but definitive data for the causes of resistance remain unclear. There are several genes that
encode α– and β–tubulins and different tubulins also arise from different post-translational
modifications [41]. Such structural diversity makes comparative analysis between tubulins
in drug-sensitive and drug-resistant cell lines difficult [42]. Exposure to taxane creates
somatic mutations in tubulins, but the relationship of somatic mutations to resistance
remains unclear, even for those mutations near the taxane binding site [43]. While an early
study found a relationship between mutations in the tubulin-encoding TUBB gene and
paclitaxel treatment response and clinical outcome (in tissue samples of patients with
advanced non-small-cell lung cancer) [44], numerous other genetic and mutational analysis
of the gene in cell lines and patients with lung cancer, breast cancer and ovarian cancer did
not find such a relationship [45-54], suggesting that mutations in TUBB do not play a role in
taxane resistance. Genetic and mutational analysis of the TUBB gene has been complicated
due to the presence of several pseudogenes with high homology to the wild type gene
[52,53]. Increased expression level of tubulins as a mechanism for resistance remains
contradictory, although there is growing evidence that this does lead to resistance for
particular tubulins [43]. Recently, high levels of chromosomal instability, and the genes
involved in this instability, have been found to be related to taxane resistance [55]
Pharmacogenetics
The impact of genetic variants on taxane response is unclear: several studies did not find
relationships between polymorphisms of genes in the taxane pathway, while others did. For
example, in a large study (n=914) of ovarian cancer patients from the Scottish Randomized
Trial in Ovarian Cancer (SCOTROC) phase III trial who were treated at presentation with
carboplatin and taxane regimens, no association between polymorphisms of genes in the
pathway and taxane response was found [56]. This study assessed polymorphisms in 11
genes (ABCB1, ABCC1, ABCC2, ABCG2, CDKN1A, CYP1B1, CYP2C8, CYP3A4, CYP3A5,
MAPT, and TP53) and found no reproducible significant associations between genotype and
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outcome or toxicity [56]. Similarly, in two other studies, no significant association was seen
between ABCB1, ABCG2, CYP1B1, CYP3A4, CYP3A5 and CYP2C8 genotypes and
paclitaxel clearance or ABCB1, CYP2C8, CYP3A4 and CYP3A5 and paclitaxel clearance
[57,58].
In contrast, other studies of genes in the taxane pathway did find associations between
polymorphisms of the genes and either patient survival or drug response. With respect to
survival, one study found rs1056836, CYP1B1*3 (4326 C>G; L432V) allele, was
significantly associated with progression-free survival, independent of paclitaxel clearance
[57]. The same SNP was also associated with survival in patients receiving docetaxel [59].
In a recent study of patients with metastatic breast cancer, the synonymous variant
rs1045642 (ABCB1: 3435 C>T), showed a significantly lower disease control rate and lower
overall survival rate than the CC genotype for the variant allele [60].
Other small studies have found associations between variants of ABCB1 and taxane
pharmacokinetics. One small study of Japanese patients found associations with ABCB1
polymorphisms, including paclitaxel pharmacokinetics and ABCB1 variants [61]. Another
small study of Japanese patients found that those with the ABCB1:3435C>T (rs1045642)
allele had a significantly higher AUC of a paclitaxel metabolite when compared to those
possessing the 3435C allele[62]. Other studies associated ABCB1: 2677G>T/A with
response to paclitaxel [63], response to taxane- and platinum-based chemotherapy [64] and
gastrointestinal toxicity [64]. A combination of ABCB1:2677G>T/A and ABCB1:3435C>T
(rs1045642) genotypes have been associated with neutropenia from paclitaxel therapy [65].
A recent small study of Caucasian patients found that the interindividual variability in
paclitaxel clearance to be related to variants in ABCB1; in particular, patients heterozygous
for G/A in position 2677 in ABCB1 had a significantly higher clearance of paclitaxel than
most other ABCB1 variants [66].
That same study found variability in paclitaxel clearance to also be related to CYP2C8
genotype; the CYP2C8*3 had lower clearance of paclitaxel [66].. Another recent small study
of docetaxel clearance found greater clearance with patients with the CYP3A4*1B and
CYP3A5*1A alleles [35]. Most of these findings remain to be validated.
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Representation of known candidate genes involved in the pharmacokinetics and
pharmacodynamics of taxanes.
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